Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/30/2025

Management of Cytomegalovirus Infection

Introduction to CMV Infection Management

  • Cytomegalovirus (CMV) infection is a significant concern in immunocompromised patients, including those on ruxolitinib, and requires careful management to prevent severe complications 1, 2

Treatment Approach

  • For patients on ruxolitinib with CMV infection, combination therapy with ganciclovir and foscarnet may be considered for severe cases or ganciclovir-resistant CMV, as recommended by the Clinical Infectious Diseases guideline 1
  • The American Society of Clinical Oncology suggests considering temporary adjustment of ruxolitinib dosing in severe cases of CMV infection, with temporary discontinuation potentially necessary, while for mild to moderate CMV viremia, continuing ruxolitinib while treating CMV infection is advised 2
  • First-line therapy for CMV viremia involves IV ganciclovir 5 mg/kg every 12 hours for 2-3 weeks, as recommended by the National Comprehensive Cancer Network and Clinical Infectious Diseases 3, 1
  • Alternative options for patients who do not tolerate ganciclovir or develop resistance include IV foscarnet 60 mg/kg every 8 hours or 90 mg/kg every 12 hours, as recommended by the National Comprehensive Cancer Network 3
  • Options for resistant CMV include:

    Option Description
    First option Foscarnet
    Second option Cidofovir
    Severe cases Combination therapy with ganciclovir and foscarnet

Monitoring and Maintenance

  • Weekly CMV viral load monitoring is essential during treatment, as recommended by the National Comprehensive Cancer Network 3
  • The minimum treatment duration is 2-3 weeks and until CMV is undetectable by PCR, with post-treatment monitoring continuing for at least 4 weeks after completing therapy, as recommended by the National Comprehensive Cancer Network 3
  • Maintenance therapy should be considered if the patient has ongoing severe immunosuppression or chronic GVHD, according to the National Comprehensive Cancer Network 3
  • Complete blood counts, serum electrolytes, and renal function tests should be monitored twice weekly during induction and weekly thereafter, according to the National Comprehensive Cancer Network 3
  • Laboratory monitoring should include complete blood counts and serum electrolytes twice weekly during induction therapy and once weekly thereafter, with monitoring for neutropenia, thrombocytopenia, and renal dysfunction, as advised by the American Society of Health-System Pharmacists and the American Society of Clinical Oncology 5, 6

Considerations for Ruxolitinib Use

  • The National Comprehensive Cancer Network suggests being aware of the potential for ruxolitinib to cause immunosuppression, increasing the risk of opportunistic infections including CMV, and thus necessitating careful monitoring and management, although the specific guideline reference is not provided in the text, the principle is key to patient care 2
  • The Infectious Diseases Society of America recommends monitoring for drug interactions between antivirals and ruxolitinib, with dose adjustments potentially needed for both medications, although the specific guideline is not provided in the text, the principle is crucial for patient management 2

Special Populations

  • Allogeneic HCT recipients should receive weekly CMV viral load monitoring for preemptive therapy, and consider letermovir as primary prophylaxis for CMV-seropositive recipients, with a surveillance period of 3-6 months post-transplant 3
  • Solid organ transplant recipients should receive preemptive therapy based on viral load monitoring, with a treatment duration of minimum 2 weeks and until CMV is undetectable 3
  • Patients with steroid-resistant IBD and CMV should receive ganciclovir (5 mg/kg IV twice daily for 2-3 weeks) and consider discontinuing immunosuppressants in severe cases 7
  • In localized CMV colitis, most immunosuppressants can be maintained, but consider tapering corticosteroids and temporary discontinuation of thiopurines due to higher risk of CMV reactivation, as recommended by the European Crohn’s and Colitis Organisation and the American Gastroenterological Association 6, 8

Diagnosis and Surgical Considerations

  • The gold standard for diagnosing CMV colitis is colonic biopsy with histology and immunohistochemistry (IHC) showing characteristic "owl's eye" inclusions, with 92-100% specificity, as recommended by the European Crohn’s and Colitis Organisation and the American Gastroenterological Association 8, 6
  • Supporting tests for CMV colitis include:

    Test Sensitivity Specificity
    Colonic tissue CMV DNA PCR improved sensitivity -
    Whole blood leukocyte DNA PCR 65-100% 40-92%
  • Surgical evaluation should be considered for severe conditions such as toxic megacolon, fulminant colitis, or perforation, as recommended by the American College of Surgeons and the World Society of Emergency Surgery 6, 9
  • CMV colitis should be considered in all patients with acute severe ulcerative colitis, to avoid delayed diagnosis, as emphasized by the American Gastroenterological Association 8

Side Effects and Interactions

  • Ganciclovir and valganciclovir can cause bone marrow suppression, foscarnet can cause nephrotoxicity and electrolyte disturbances, and cidofovir can cause substantial nephrotoxicity and potential ocular toxicity 3
  • Monitor for common side effects of ganciclovir, including neutropenia, thrombocytopenia, and renal dysfunction, which can mimic systemic CMV infection, as stated by the European Hematology Association 6
  • Dose adjustment is needed when valganciclovir is coadministered with certain immunosuppressants, and letermovir lacks HSV/VZV coverage, so HSV/VZV prophylaxis should be continued when using letermovir 3

Multidisciplinary Approach

  • A multidisciplinary approach is recommended, engaging infectious disease specialists early, especially for complex cases, as stated by the Infectious Diseases Society of America 6